靶向癌症基因组。 - Suppr

Drugging cancer genomes.

作者信息

Workman Paul, Al-Lazikani Bissan

机构信息

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.

出版信息

Nat Rev Drug Discov. 2013 Dec;12(12):889-90. doi: 10.1038/nrd4184.

DOI:10.1038/nrd4184

PMID:24287764

Abstract

摘要

相似文献

Drugging cancer genomes.

Nat Rev Drug Discov. 2013 Dec;12(12):889-90. doi: 10.1038/nrd4184.

Paul Workman: Drugging the Cancer Genome.

Trends Cancer. 2016 Oct;2(10):544-548. doi: 10.1016/j.trecan.2016.10.004.

Editorial: target therapy in brain tumours and metastases.

Curr Cancer Drug Targets. 2012 Mar;12(3):185. doi: 10.2174/156800912799277458.

G-quadruplexes: selective DNA targeting for cancer therapeutics?

Expert Rev Clin Pharmacol. 2011 Mar;4(2):139-42. doi: 10.1586/ecp.11.4.

Deal watch: MSD buys in to emerging epigenetic cancer target.

Nat Rev Drug Discov. 2016 Mar;15(3):153. doi: 10.1038/nrd.2016.20.

Targeting the microRNA-regulating DNA damage/repair pathways in cancer.

Expert Opin Biol Ther. 2014 Nov;14(11):1667-83. doi: 10.1517/14712598.2014.950650. Epub 2014 Sep 5.

[Forefront of Cancer Targeting Therapy].

Yakugaku Zasshi. 2018;138(7):901-902. doi: 10.1248/yakushi.17-00220-F.

The promise of targeted therapy: cancer drugs become more specific.

Cleve Clin J Med. 2004 Jul;71(7):551-60. doi: 10.3949/ccjm.71.7.551.

Personalized medicine in oncology: next generation.

Nat Rev Drug Discov. 2011 Dec 1;10(12):895-6. doi: 10.1038/nrd3603.

Targeting epithelial-to-mesenchymal transition for cancer therapy.

Curr Pharm Des. 2015;21(10):1239. doi: 10.2174/1381612821666141211155017.

引用本文的文献

Phenotype and target-based chemical biology investigations in cancers.

Natl Sci Rev. 2019 Nov;6(6):1111-1127. doi: 10.1093/nsr/nwy124. Epub 2018 Nov 1.

canSAR: update to the cancer translational research and drug discovery knowledgebase.

Nucleic Acids Res. 2021 Jan 8;49(D1):D1074-D1082. doi: 10.1093/nar/gkaa1059.

PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.

Genome Biol. 2020 Jul 30;21(1):181. doi: 10.1186/s13059-020-02092-2.

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.

PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.

Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.

F1000Res. 2018 Mar 12;7:308. doi: 10.12688/f1000research.13679.1. eCollection 2018.

A comprehensive map of molecular drug targets.

Nat Rev Drug Discov. 2017 Jan;16(1):19-34. doi: 10.1038/nrd.2016.230. Epub 2016 Dec 2.

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

本文引用的文献

Mutational landscape and significance across 12 major cancer types.

Nature. 2013 Oct 17;502(7471):333-339. doi: 10.1038/nature12634.

Cancer genome landscapes.

Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.

Objective assessment of cancer genes for drug discovery.

Nat Rev Drug Discov. 2013 Jan;12(1):35-50. doi: 10.1038/nrd3913.

canSAR: an integrated cancer public translational research and drug discovery resource.

Nucleic Acids Res. 2012 Jan;40(Database issue):D947-56. doi: 10.1093/nar/gkr881. Epub 2011 Oct 19.

A census of human cancer genes.

Nat Rev Cancer. 2004 Mar;4(3):177-83. doi: 10.1038/nrc1299.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Drugging cancer genomes.

Nat Rev Drug Discov. 2013 Dec;12(12):889-90. doi: 10.1038/nrd4184.

Paul Workman: Drugging the Cancer Genome.

Trends Cancer. 2016 Oct;2(10):544-548. doi: 10.1016/j.trecan.2016.10.004.

Editorial: target therapy in brain tumours and metastases.

Curr Cancer Drug Targets. 2012 Mar;12(3):185. doi: 10.2174/156800912799277458.

G-quadruplexes: selective DNA targeting for cancer therapeutics?

Expert Rev Clin Pharmacol. 2011 Mar;4(2):139-42. doi: 10.1586/ecp.11.4.

Deal watch: MSD buys in to emerging epigenetic cancer target.

Nat Rev Drug Discov. 2016 Mar;15(3):153. doi: 10.1038/nrd.2016.20.

Targeting the microRNA-regulating DNA damage/repair pathways in cancer.

Expert Opin Biol Ther. 2014 Nov;14(11):1667-83. doi: 10.1517/14712598.2014.950650. Epub 2014 Sep 5.

[Forefront of Cancer Targeting Therapy].

Yakugaku Zasshi. 2018;138(7):901-902. doi: 10.1248/yakushi.17-00220-F.

The promise of targeted therapy: cancer drugs become more specific.

Cleve Clin J Med. 2004 Jul;71(7):551-60. doi: 10.3949/ccjm.71.7.551.

Personalized medicine in oncology: next generation.

Nat Rev Drug Discov. 2011 Dec 1;10(12):895-6. doi: 10.1038/nrd3603.

Targeting epithelial-to-mesenchymal transition for cancer therapy.

Curr Pharm Des. 2015;21(10):1239. doi: 10.2174/1381612821666141211155017.

引用本文的文献

Phenotype and target-based chemical biology investigations in cancers.

Natl Sci Rev. 2019 Nov;6(6):1111-1127. doi: 10.1093/nsr/nwy124. Epub 2018 Nov 1.

canSAR: update to the cancer translational research and drug discovery knowledgebase.

Nucleic Acids Res. 2021 Jan 8;49(D1):D1074-D1082. doi: 10.1093/nar/gkaa1059.

PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.

Genome Biol. 2020 Jul 30;21(1):181. doi: 10.1186/s13059-020-02092-2.

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.

PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.

Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.

F1000Res. 2018 Mar 12;7:308. doi: 10.12688/f1000research.13679.1. eCollection 2018.

A comprehensive map of molecular drug targets.

Nat Rev Drug Discov. 2017 Jan;16(1):19-34. doi: 10.1038/nrd.2016.230. Epub 2016 Dec 2.

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

本文引用的文献

Mutational landscape and significance across 12 major cancer types.

Nature. 2013 Oct 17;502(7471):333-339. doi: 10.1038/nature12634.

Cancer genome landscapes.

Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.

Objective assessment of cancer genes for drug discovery.

Nat Rev Drug Discov. 2013 Jan;12(1):35-50. doi: 10.1038/nrd3913.

canSAR: an integrated cancer public translational research and drug discovery resource.

Nucleic Acids Res. 2012 Jan;40(Database issue):D947-56. doi: 10.1093/nar/gkr881. Epub 2011 Oct 19.

A census of human cancer genes.

Nat Rev Cancer. 2004 Mar;4(3):177-83. doi: 10.1038/nrc1299.

Drugging cancer genomes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献